XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.1

Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables) - Melt Pharmaceuticals [Member]

3 Months Ended

Mar. 31, 2019

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Melt is summarized below:

		For the
		Three months ended
		March 31, 2019
Revenues, net		$	-
Loss from operations			647
Net loss		$	(647	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Melt is summarized below:

		March 31,
		2019
Current assets		$	10,269
Non current assets			2
Total assets		$	10,271
Total liabilities		$	950
Total preferred stock and stockholders’ equity			9,321
Total liabilities and stockholders’ equity		$	10,271

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: